[(2-chloro-3,4-difluorophenyl)methyl]amine | 1001462-84-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(2-chloro-3,4-difluorophenyl)methyl]amine
• 英文别名: 2-Chloro-3,4-difluorobenzylamine；(2-chloro-3,4-difluorophenyl)methanamine
• CAS: 1001462-84-5
• 化学式: C₇H₆ClF₂N
• 分子量: 177.581
• InChiKey: ULORPEWFMWWDMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [(2-chloro-3,4-difluorophenyl)methyl]amine 在 对甲苯磺酸 N-乙基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N-甲基吡咯烷酮 、 二氯甲烷 为溶剂， 反应 21.17h， 生成 N-[(2-chloro-3,4-difluorophenyl)methyl]-3-methyl-1-[(4-methyl-1H-imidazol-5-yl)methyl]-2-oxo-4-imidazolidinecarboxamide
  参考文献：
  名称：

  WO2008/119825

  摘要：

  公开号：

文献信息

• Imidazolidine Carboxamide Derivatives as P2X7 Modulators
  申请人：Beswick Paul John

  公开号：US20100075968A1

  公开（公告）日：2010-03-25

  The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.

  本发明涉及式（I）的化合物或其药学上可接受的盐：这些化合物或盐可以调节P2X7受体功能，并能拮抗P2X7受体上ATP的效应（P2X7受体拮抗剂）。本发明还提供了这些化合物或盐的使用，或其制成的药物组合物，在治疗或预防由P2X7受体介导的疾病/疾病中，例如疼痛，炎症或神经退行性疾病，特别是疼痛，例如炎症性疼痛，神经病理性疼痛或内脏疼痛。
• Imidazolidine carboxamide derivatives as P2X7 modulators
  申请人：Glaxo Group Limited

  公开号：US07932282B2

  公开（公告）日：2011-04-26

  The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.

  本发明涉及式（I）的化合物或其药学上可接受的盐：这些化合物或盐调节P2X7受体功能，并能对抗P2X7受体上ATP的影响（P2X7受体拮抗剂）。本发明还提供了这些化合物或盐的使用，或其制药组合物，在治疗或预防由P2X7受体介导的疾病/疾病中，例如疼痛、炎症或神经退行性疾病，特别是疼痛，如炎性疼痛、神经病理性疼痛或脏器疼痛。
• Tetrahydroquinoline derivatives as P2X7 receptor antagonists
  申请人：RaQualia Pharma Inc.

  公开号：US11077100B2

  公开（公告）日：2021-08-03

  The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.

  本发明涉及本发明的四氢喹啉衍生物或其药学上可接受的盐或其原药、其制备工艺、含有它们的药物组合物以及它们在治疗通过 P2X7 受体介导的各种疾病中的用途。
• IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS
  申请人：Glaxo Group Limited

  公开号：EP2142512A2

  公开（公告）日：2010-01-13
• TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
  申请人：RaQualia Pharma Inc.

  公开号：US20200405706A1

  公开（公告）日：2020-12-31

  The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.